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ABSTRACT
Double-stranded RNAs are powerful agents for
silencing gene expression in the cytoplasm of mam-
malian cells. The potential for duplex RNAs to
control expression in the nucleus has received less
attention. Here, we investigate the ability of small
RNAs to redirect splicing. We identify RNAs target-
ing an aberrant splice site that restore splicing and
production of functional protein. RNAs can target
sequences within exons or introns and affect the
inclusion of exons within SMN2 and dystrophin,
genes responsible for spinal muscular atrophy and
Duchenne muscular dystrophy, respectively. Duplex
RNAs recruit argonaute 2 (AGO2) to pre-mRNA
transcripts and altered splicing requires AGO2 ex-
pression. AGO2 promotes transcript cleavage in the
cytoplasm, but recruitment of AGO2 to pre-mRNAs
does not reduce transcript levels, exposing a differ-
ence between cytoplasmic and nuclear pathways.
Involvement of AGO2 in splicing, a classical
nuclear process, reinforces the conclusion from
studies of RNA-mediated transcriptional silencing
that RNAi pathways can be adapted to function
in the mammalian nucleus. These data provide a
new strategy for controlling splicing and expand
the reach of small RNAs within the nucleus of mam-
malian cells.
INTRODUCTION
Newly synthesized transcripts (pre-mRNAs) contain
intervening sequences (introns). These introns must be
excised from the pre-mRNA by the spliceosome, a
ribonucleoprotein complex. The remaining portions of
the pre-mRNA (exons) are then spliced to form the
mature mRNA that codes for proteins. Splicing occurs
in the nucleus and spliced transcripts are exported into
the cytoplasm. Splicing usually does not produce a
single mRNA species for each gene. Instead, pre-
mRNAs are spliced in alternate ways, leading to produc-
tion of different proteins. This phenomenon is known as
alternative splicing and is observed in >90% of all human
genes (1).
Approximately 60% of disease-causing point mutations
are related to defective splicing (2) and chemical agents
that redirect splicing may promote production of protein
isoforms to compensate for genetic defects (3–5). For
example, Duchenne muscular dystrophy is an incurable
disease caused by mutations in the DMD gene-encoding
dystrophin protein (6). Agents that promote alternative
splicing can yield a truncated version of dystrophin
that is naturally found in patients suffering from a more
mild disease, Becker’s muscular dystrophy. Induction of
truncated dystrophin might convert a fatal genetic disease
into a condition where patients experience a normal
lifespan and a good quality of life.
Efforts to develop chemical agents to redirect splicing
have focused on single-stranded oligomers including
PNAs (7), LNAs (8), morpholino oligomers (9) and
20-modiﬁed oligonucleotides (10). Phase I and Phase I-2a
clinical trials have shown promising results. Both intra-
muscular (11) and systemic administration (12) have par-
tially restored dystrophin expression and systemic
administration also yielded signiﬁcant improvements in
muscle function. While this progress is promising, the
challenges facing drug development are high and there
remains an urgent need to explore multiple strategies.
Short-interfering RNAs (siRNAs) offer another
strategy for recognizing mRNA. siRNAs are powerful
tools for gene silencing in the laboratory and are being
tested in several clinical trials (13). Typically, siRNAs
bind argonaute 2 (AGO2) (14), recognize mRNA in the
cytoplasm, guide cleavage of the RNA target by AGO2
and inhibit gene expression. While cleavage of an mRNA
target is desirable for inhibiting gene expression,
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ecting splicing. It may be possible, however, to separate
the recognition and cleavage functions of AGO2. We pre-
viously observed that small duplex RNAs can target
non-coding transcripts and trigger transcriptional
silencing or activation of adjacent genes (15,16). This
gene modulation requires AGO2 protein and recognition
occurs without causing cleavage of the targeted non-
coding transcripts.
This observation led us to hypothesize that small RNAs
might have the ability to alter another nuclear event
splicing. To test this hypothesis, we have conducted a
detailed analysis of duplex RNAs complementarity to
key sequences within introns and exons. For three differ-
ent genes, we ﬁnd that duplex RNAs promote intron/exon
exclusion. The mechanism involves AGO2 protein, recog-
nition of pre-mRNA and does not involve changes in
chromatin. These data provide an unexpected mechanism
for RNA-mediated alteration of splicing and further dem-
onstrate the reach of RNAi pathways into the nuclei of
mammalian cells. The ability of small RNAs to alter
splicing provides another option for developing thera-
peutic nucleic acids.
MATERIALS AND METHODS
General
Unless otherwise noted, duplex RNAs were purchased
from Integrated DNA Technologies (IDT, Coralville,
IA, USA). Duplex RNAs complementary to AGO1 or
AGO2 mRNA were provided by Dharmacon (16). 20-O-
methyl RNA was obtained from Sigma. Trichostatin A
(TSA) and 5-aza-20-deoxycytidine (5-Aza-dC) were
obtained from Sigma. All conclusions derive from
multiple independent experiments.
Cell culture
HeLa pLuc/705 cells were provided from Dr Ryszard
Kole (University of North Carolina) and cultured at
37 C and 5% CO2 in Dulbecco’s Modiﬁed Eagle’s
Medium (DMEM) (Sigma, D5796) supplemented with
10% heat-inactivated fetal bovine serum (Sigma), 1%
Sodium Pyruvate (Sigma) and 0.5% MEM non-essential
amino acids (Sigma). Patient-derived SMA type I homo-
zygous ﬁbroblast cell (GM03813; Coriell Cell
Repositories, Camden, NJ, USA) were cultured in
Minimum Essential Medium Eagle (MEM; Sigma,
M4655) supplemented with 10% (v/v) fetal bovine serum
and 1% MEM non-essential amino acids (Sigma, M7145).
Patient-derived Duchenne Muscular Dystrophy ﬁbroblast
cell (GM03429; Coriell Cell Repositories) were cultured in
Minimum Essential Medium Eagle (MEM; Sigma,
M4655) supplemented with 15% (v/v) fetal bovine serum
and 1% MEM non-essential amino acids (Sigma, M7145).
Transfections
HeLa pLuc/705 cells were plated 24h in advance so that
their density on the day of transfection was  90%. For
GM03813 ﬁbroblast transfection, cells were plated at a
density of  1.2(10)
5 per well of a 6-well plate 24h
before transfection. Cells were transfected with siRNAs
using RNAiMAX (Invitrogen) (15,16). Unless indicated
otherwise, total RNA was isolated 24h after transfection
with Trizol (Invitrogen) for RT–PCR.
Luciferase assay
Twenty-four hours after transfection, cells were washed
twice with 1XPBS and lysed with Passive Lysis Buffer
(Promega, Madison, WI, USA). Protein concentrations
were determined by the bicinchoninic acid (BCA assay).
Luciferase activity was measured on a Synergy 2
Multi-Mode Microplate Reader (BioTek, Winooski, VT,
USA) by mixing 50ml of cell lysate with 100mlo f
Luciferase Assay substrate (Promega). Luciferase expres-
sion was calculated as relative luminescence units (RLU)
per microgram protein and shown as fold increase in
luminescence compared with negative control. All experi-
ments were performed in multiple independent transfec-
tions. Error bars are standard deviation.
RT–PCR
To generate cDNA, total RNA was extracted and treated
with DNase I (Worthington Biochemical) at 25mM
for 10min. Reverse transcription was performed using
high-capacity reverse transcription kit (Applied
Biosystems) according to the manufacturer’s protocol.
Generally, 2.0mg of total RNA was used per 20mlo f
reaction mixture. PCR was performed on a 7500
real-time PCR system (Applied Biosystems) using iTaq
SYBR Green Supermix (BioRad) using the following
primers for HeLa cell: Luci forward primer 50-TTGATA
TGTGGATTTCGAGTCGTC-30 and Luci reverse primer
50-TGT CAATCAGAGTGCTTTTGGCG-30. PCR for
SMA cell used forward primer: 50-CCTCCCATATGTC
CAGATTCTCTTGATG-30 and reverse primer: 50-CAG
ATGGTTTTTCAAAATAGAGTCC-30. For DMD,
primary PCR was carried out with outer primer set (44
FP: 50-GATATAAAGATATTTAATCAGTGGCTAA;
83 RP: 50-CCGTAATGATTGTTCTAGCCTCTTGAT
TGC-30) for 28 cycles. Then, nested PCR was performed
with1ml of primary PCR product as template using an
inner primer set (61 FP: 50-TCAGTGGCTAACAGAAG
CTGAACAGTTT-30 and 83RP) for 30 cycles.
All the PCR products were separated on a 2% agarose
gel and visualized on an AlphaImager. The bands were
quantiﬁed using ImageJ software (Rasband, W.S.,
ImageJ, US National Institutes of Health, Bethesda,
MD, USA, http://rsb.info.nih.gov/ij/, 1997–2007).
Splicing correction on HeLa pLuc705 model was
calculated as a percentage of the total amount of spliced
mRNA: correct mRNA 100/(correct mRNA+aberrant
mRNA). For SMA, inclusion of exon 7 was calculated as
a percentage of the total amount of spliced mRNA,
i.e. included mRNA 100/(included mRNA+skipped
mRNA). The increment of aberrant mRNA was
calculated as a fold mRNA level above a control sample.
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HeLa Luc/705 cells were grown in 150cm
2 dishes and
transfected with duplex RNAs. Cells ( 4 10
7) were har-
vested 24h after transfection and nuclear fraction was
isolated (15–17). A nuclear lysis buffer [150mM KCl,
20mM Tris–HCl 7.4, 3mM MgCl2, 0.5% NP-40,
1 Roche protease inhibitors cocktail, RNAse in
(50 U/ml ﬁnal)] was added to the nuclei (Note: no formal-
dehyde cross-linking is used in this protocol) (16,17). The
mixture was left on ice for 10min. After vigorous vortex-
ing and pipetting, nuclei were freeze-thawed three times in
liquid nitrogen and a 22 C water bath. Insoluble material
was removed by centrifugation at maximum speed
for 15min at 4 C. Nuclear extracts were quickly frozen
in liquid nitrogen and stored at  80 C. Sixty microliters
of protein A/G agarose Plus was washed with
phosphate-buffered saline (1 PBS, pH 7.4) and
incubated with 5mg of anti-AGO1(4B8, gift from from
Dr Gunter Meister, Universita ¨ t Regensburg) and
anti-AGO2 (4G8, 011-22033, Wako) antibody in 0.5ml
at 4 C with gentle agitation for 2h. After one wash with
1 PBS and one wash with nuclear lysis buffer, beads
were incubated with nuclear cell lysate under constant
rotation for 3h at 4 C. After washing with nuclear lysis
buffer (three times), the beads were then treated with
elution buffer (1% SDS, 0.1M NaHCO3 and RNase in-
hibitor). Following proteinase K treatment, RNA extrac-
tion and precipitation, samples were treated with
recombinant DNase I followed by reverse transcription.
Corresponding cDNA was ampliﬁed using reverse primer
complementary to Luc/705 pre-mRNA (50-AAAACGAT
CCTGAGACTTCCACACTGATG-30) with Luci forward
primer (Supplementary Figure S1i) and GAPDH mRNA
(Applied Biosystems).
Results were normalized by measuring two parameters
simultaneously: (i) binding of Luc/705 pre-mRNA to IgG,
to anti-Ago1 and to anti-Ago2 antibodies as an indicator
of fold enrichment of Luc/705 pre-mRNA in Ago1 or
Ago2 IP relative to IgG IP; (ii) binding of GAPDH
mRNA (in both Ago1 or Ago2 IP and IgG IP) to the
above antibodies as an indicator of a housekeeping
control for background binding.
Chromatin immunoprecipitation assay
ChIP assays were performed as described (16). Anti-
trimethyl-histone H3 (Lys27) and anti-dimethyl-histone
H3 (Lys9) antibodies were supplied by Millipore.
RESULTS
Duplex RNAs promote exon exclusion
To examine the effect of duplex RNAs on splicing, we
used an engineered HeLa cell line (HeLa pLuc/705) that
expresses a chromosomally encoded luciferase gene inter-
rupted by intron 2 from the b-globin gene (18) (Figure 1a).
The b-globin intron has been mutated to introduce a new
splice site that causes retention of a fragment of the intron
and production of inactive luciferase protein. Antisense
oligonucleotides complementary to the introduced splice
site redirect splicing toward normal length luciferase
protein. HeLa pLuc/705 is an excellent model for
splicing studies because splicing can be monitored at the
RNA level by semi-quantitative PCR or at the protein
level by luciferase activity.
We designed several duplex RNAs that were fully com-
plementary to sequences near the introduced splice site
within the b-globin-derived intron (Supplementary
Table S1). We observed that duplex 709 was a potent
activator of luciferase expression while duplex RNAs
targeting nearby sites were less active (Figure 1b and c;
Supplementary Figure S1a). Half-maximal activity was
achieved by adding 10nM duplex while previously
characterized (18) antisense oligomer 705OMe
(a single-stranded oligomer composed of 20-O-methyl
RNA bases) required >200nM (Figure 1d and e;
Supplementary Figure S1b and c). These experiments
established that fully complementary duplex RNAs were
capable of entering the nucleus and shifting splicing to
efﬁciently exclude an intron.
In the experiments, the component single strands that
make up the RNA duplexes were annealed at equimolar
ratios to minimize the presence of single-stranded RNA.
The extent of duplex formation was conﬁrmed by moni-
toring thermal denaturing/renaturing and by determining
melting temperatures. We have previously observed that
single-stranded RNA is much less stable than duplex
RNA. In cell culture medium, single-stranded RNA has
a half-life of <30s, while duplex RNAs are stable for up to
72h (19). Chemical modiﬁcations can increase the stability
of RNA, but the RNA used in this study was unmodiﬁed
and the single strands would not be expected to survive
initial contact with cell culture media. Consistent with this
assumption, we have found that single-stranded RNAs are
inactive when added to cells (Hu, J. and Corey, D.R.,
unpublished data).
RNA-mediated alternative splicing tolerates non-seed
sequence mismatches
Some sequences that affect splicing are located within
exons. Duplex RNAs that target exons would have the
potential to act like standard siRNAs and cause
cleavage of mature mRNA in the cytoplasm. Such
cleavage would be undesirable if preservation of the
exon-included spliceform was necessary. It is possible
to disrupt cleavage by introducing mismatched bases
located within the central region (bases 10 or 11) (20,21)
of the duplex RNA. The presence of centrally located
mismatches should, therefore, avoid destruction of
mature mRNA and increase the options for obtaining dif-
ferent ratios of the desired spliceforms.
To test if mismatch-containing RNAs could be active
splice modulators and expand the versatility of our
approach, we tested mismatched duplexes targeted to
sequences near the aberrant splice site for their ability to
redirect splicing. Similar to our results with fully comple-
mentary duplex RNA (709), only duplex 709mm was an
efﬁcient agent for redirecting splicing (Figure 1f;
Supplementary Figure S1d and e). When introduced into
1242 Nucleic Acids Research, 2012,Vol.40, No. 3cells at varying concentrations, 709mm achieved half
maximal activity at 10nM (Supplementary Figure S1f).
After observing that one centrally located mismatch
was tolerated, we tested whether multiply mismatched
duplexes or duplexes were capable of redirecting
splicing. We tested a duplex with three centrally located
mismatches within a duplex RNA (709mmm) and
observed altered splicing (Figure 1g; Supplementary
Figure S1g and h). Duplex RNAs containing multiple
mismatches are similar in structure to miRNAs and
their ability to alter splicing suggests that some
miRNAs might be capable of changing the ratio of
spliceforms.
Recognition of RNA substrates is highly dependent on
binding of the seed sequence, a critical region located
at bases 2–8 of the duplex RNA. We had previously
observed that introduction of a single mismatch at
position 6 within the seed sequence abolishes post-
transcriptional gene silencing (PTGS) when duplex
RNAs target an mRNA in the cytoplasm (22). Just
one mismatch within the seed sequence (709mm6)
made the duplex inactive (Figure 1g, Supplementary
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Figure 1. Duplex RNAs alter splicing of luciferase pre-mRNA in HeLa Luc/705 cells. (a) Left: schematic showing splicing of pre-mRNA. Boxes
represent sequences derived from luciferase exons. The intervening region is derived from human b-globin inton 2 with T/G mutation at nucleotide
705. The 30 cryptic site and target site for duplex 705 is noted. Right: target sites for duplex RNAs within the b-globin inton 2. The mutation site is in
bold. (b) PCR ampliﬁcation followed by gel electrophoresis to separate aberrant and correct splice products upon the addition of duplex RNAs. (c)
Increase in luciferase activity upon the addition of duplex RNAs. (d and e) Effect on splicing and luciferase activity from increasing concentrations of
duplex RNA 709. (f) PCR ampliﬁcation followed by gel electrophoresis to separate aberrant and correct splice products after adding
mismatch-containing RNA duplexes. (g) Effect on splicing of multiple or seed sequence mismatches. Duplex RNAs were transfected into
HeLa-derived pLUC/705 cells at 50nM unless otherwise noted. CM: non-complementary control duplex. Error bars represent standard deviation
(SD). Experiments were performed in triplicate or quadruplicate.
Nucleic Acids Research,2012, Vol.40, No. 3 1243Figure S1g and h). The critical importance of position 6
for both RNA-mediated alteration of splicing and PTGS
is consistent with both processes sharing similar protein
machinery. The ﬁnding that a single mismatch (amid 18
fully complementary bases) abolishes activity also suggests
a powerful selectivity for recognition of the target
pre-mRNA.
Active RNAs do not cause cleavage of pre-mRNA
Recognition of mRNA by fully complementary duplex
RNAs in the cytoplasm is associated with cleavage of
the target RNA (14). To investigate the mechanism of
RNA-mediated splice correction and the potential
impact of RNA cleavage, we tested whether the duplex
RNAs used in our experiment affect RNA levels. We
observed several lines of evidence suggesting that RNAs
can target introns without reducing RNA levels: (i)
semi-quantitative PCR showed that levels of luciferase
RNA remain relatively constant (Figure 1b, d, f and g);
(ii) measurement of luciferase activity indicate that the
production of luciferase protein was being increased
rather than reduced (Figure 1c and e; Supplementary
Figure S1) and (iii) quantitative PCR reveals no signiﬁcant
change in pre-mRNA levels (Figure 2a). It is possible that
some cleavage of target RNA sequences is occurring, but
such cleavage does not affect the levels of RNA or
increased production of active protein. Our data indicate
that, unlike the well-known mechanism for standard
post-transcriptional gene silencing (PTGS) in the cyto-
plasm, RNA-mediated alteration of splicing in the
nucleus can avoid cleavage of the target transcript.
AGO2 plays primary role in pre-mRNA recognition
AGO proteins are critical components of the cellular ma-
chinery for recognizing small RNAs and we hypothesized
that they might also be involved in RNA-mediated control
of splicing. There are four AGO proteins in human cells
(AGO1-4). AGO2 is responsible for post-transcriptional
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Figure 2. Mechanism of redirecting splicing by duplex RNAs. (a) Effect of duplex RNAs on levels of luciferase pre-mRNA. (b) Western blot
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1244 Nucleic Acids Research, 2012,Vol.40, No. 3gene silencing (14) but AGO1 has been reported to be
involved in altering splicing through recognition of
non-coding RNA (23). AGO2 is found in cytoplasmic
p-bodies (24,25), but has also been reported to be in the
nucleus (16,17,26,27). We identiﬁed both AGO1 and
AGO2 within puriﬁed nuclei from HeLa pLuc/705 cells
(Figure 2b).
To test which AGO variant was responsible for small
RNA-mediated alteration of splicing, we used anti-AGO1
or anti-AGO2 siRNAs to deplete cellular AGO1 or AGO2
(Supplementary Figure S2a). Inhibition of AGO1 and
AGO2 expression was not absolute, possibly because in-
hibition of AGO expression reduces the efﬁciency of gene
silencing, and a total reversal of effects on RNA splicing
would not be expected. Lowering levels of AGO2 protein
reduced the efﬁciency of RNA-mediated splice correction
and production of active luciferase (Figure 2c). Reduced
expression of AGO1 had no effect on RNA-mediated
alternative splicing or luciferase expression. We then
used RNA immunoprecipitation (RIP) to examine recruit-
ment of AGO1 and AGO2 to the luciferase transcript.
AGO2, but not AGO1, was recruited to luciferase
pre-mRNA (Supplementary Figures S1i and 2d). These
data from two independent experimental tests point
toward AGO2 being the best candidate for involvement
in the observed RNA-mediated splice correction.
No evidence for chromatin modiﬁcation
Kornblihtt has reported that duplex RNAs can induce
inclusion of exons in an AGO1-dependent manner
through complementarity to endogenous antisense tran-
scripts, inducing changes in chromatin structure and af-
fecting elongation of pre-mRNA by RNA polymerase
(23). The mechanism we observe is fundamentally differ-
ent. Our data suggest a critical role for AGO2 rather than
AGO1 (Figure 2c and d). Our data also suggest that the
pre-mRNA is that molecular target rather than an anti-
sense transcript. RNA 709mm6G with a mismatched base
at position 6 of the strand complementary to the
pre-mRNA lost the ability to redirect splicing (Figure 2e
and f; Supplementary Figure S2b), suggesting that
pre-mRNA is the molecular target. In contrast, RNA
709mm6P containing a seed-sequence mismatch relative
to a putative antisense non-coding transcript retained
the ability to alter splicing.
Inhibition of HP1a expression (Figure 3a and
Supplementary Figure 2c) or synthetic epigenetic regula-
tory agents 5-aza deoxycytidine (5-AZA-dC) or
trichostatin A (TSA) (Figure 3b) did not affect splice cor-
rection. We observed no alteration of histone marks
H3K9me2 (Figure 3c) or H3K27me3 (Figure 3d) after
treating with duplex RNA 709. Taken together, our data
suggest that RNA-mediated alternative splicing does not
necessarily require chromatin modiﬁcations or effects on
transcription and that the mechanism that we observed
differs from that previously reported.
RNA-mediated exon exclusion for SMN1 and dystrophin
To further characterize RNA-mediated alternative
splicing, we examined a gene containing both exonic and
intronic target sequences. Spinal muscular atrophy (SMA)
is an inherited neurodegenerative disorder caused by loss
or mutation of the survival motor neuron 1 (SMN1) gene
(28). A second gene, SMN2, is closely related to SMN1
but its active spliceform is not efﬁciently expressed.
Oligonucleotides that alter SMN2 splicing can increase
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Figure 3. Altered splicing is not due to chromatin changes. (a) Effect of siRNA-mediated reduction of HP1a levels on the ability of RNAs 709 and
709mm to enhance luciferase expression. (b) Effect of adding 100nM TSA and/or 10mM 5-AZA-dC on the ability of duplex RNA 709 to enhance
luciferase activity. (c and d) ChIP showing the effect of RNA 709 on H3K9me2 or H3K27me3 modiﬁcation, evaluated by primer sets designed to
amplify three different regions of the gene. Unless otherwise noted, duplex RNAs were transfected into HeLa-derived pLuc/705 cells at 50nM. CM:
non-complementary control duplex. Error bars represent standard deviation (SD). Experiments were performed in triplicate.
Nucleic Acids Research,2012, Vol.40, No. 3 1245SMN2 protein to therapeutically useful levels that com-
pensate for loss of SMN1 (29,30).
SMN2 can be spliced to directly join exons 6 and 8 or to
produce an isoform that contains exons 6–8 (Figure 4a).
We designed duplex RNAs to target sequences near
intronic splice silencers (ISSs) or an exonic splice silencer
(ESS). Duplexes I3-E16 and E1–E19 (numbering is
relative to the intron exon junction) targeted near
the intron 6/exon 7 junction, increased exclusion of exon
7 (Supplementary Table S2; Figure 4b and c). Both
duplexes were fully complementary to the target
sequence and these data demonstrated that duplex
RNAs complementary to exons could redirect alternative
splicing.
While our data suggest that AGO2 lacks the ability to
induce cleavage of pre-mRNA in the nucleus, there is no
doubt that duplex RNAs complementary to exons can
induce AGO2-mediated cleavage of mature mRNA in
the cytoplasm. The potential for cytoplasmic cleavage is
important for the outcome of RNA-mediated exon exclu-
sion because the target sequence is within exon 7 and
cleavage of mature mRNA will affect the ratio of the
two spliceforms. To test whether we could manipulate
the spliceform ratio of SMN2, we introduced mismatches
at positions known to disrupt cleavage of target RNAs by
AGO2.
Mismatch-containing duplexes I3–E16 mm and E1–E19
mm increased splicing of the 6+8 spliceform
(Supplementary Figure S3a–S3c). Exclusion of exon 7
was dose dependent (Supplementary Figure S3d–S3i).
When we directly compared the fully complementary
and mismatch-containing duplexes, we observed that
6+7+8 spliceform was better preserved upon the
addition of mismatched RNAs, consistent with our hy-
pothesis that introduction of mismatches would reduce
cleavage of exon-included mRNA in the cytoplasm
(Figure 4d). It is important to note that the change in
spliceform ratio shifts isoform production away from the
potentially therapeutic variant. It is possible that more
extensive testing of duplexes complementary to other
sites might identify compounds that enhance production
of the 6+7+8 isoform.
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Figure 4. RNAs alter splicing of SMN2 in SMA type 1 ﬁbroblast cells. (a) Left: schematic of SMN2 splicing. The dark bar within exon 7 shows the
position of the C to T transition in SMN2 relative to SMN1. Right: schematic showing the binding sites for duplex RNAs. Sequences underlined
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to T transition is bold. (b and c) Semiquantitative RT–PCR showing the effect of fully complementary duplex RNAs (100nM) on splicing of SMN2.
(d) Semiquantitative RT–PCR comparing effects of fully complementary and mismatch-containing complementary duplex RNAs (100nM) on
splicing of SMN2. ISS: intronic splicing silencer; ESS: exonic splicing silencer. CM is a non-complementary RNA duplex. Student’s t-test was
performed for evaluating statistical signiﬁcance between two study groups. **P<0.01, ***P<0.001. Error bars represent standard deviation (SD).
Experiments were performed in duplicate or quadruplicate.
1246 Nucleic Acids Research, 2012,Vol.40, No. 3As observed for duplex RNAs targeting engineered
luciferase, the action of duplex RNAs targeting SMN2
was reversed by use of siRNAs to reduce AGO2 expres-
sion while reduction of AGO1 expression did not affect
splicing (Supplementary Figure S4a and Figure 5a). The
duplex RNAs that induced exon exclusion achieved this
activity without reducing levels of SMN2 pre-mRNA
(Figure 5b), providing additional evidence that AGO2
can function in the nucleus independent from RNA
cleavage. Inhibition of HP1a, treatment with TSA or
5-AZA-dC had no effect on RNA-mediated alteration of
splicing (Supplementary Figure S4b; Figure 5c and d). As
with engineered luciferase, RNA-mediated splice modula-
tion of SMN2 appears to produce by a mechanism that
differs from that previously reported (23).
We also examined RNAs complementary to dystrophin
pre-mRNA to test their effects on splicing of dystrophin
(Figure 6a and Supplementary Table S3). We used a cell
line (GM03429) with an exon 45–50 deletion. We targeted
sequences within exon 51 because deletion of exon 51
removes a premature stop codon and can produce partial-
ly active dystrophin that may have value for treating
patients with muscular dystrophy (6). Since the target
sequence was within an exon, all duplex RNAs contained
one centrally located mismatch at either position 10 (in
one case) or 11. Two RNAs, 66 and 68/10, successfully
induced exon exclusion and production of the truncated
dystrophin characteristic of the more mild Becker’s
muscular dystrophy (Figure 6b and c). Altered splicing
of dystrophin, engineering luciferase and SMN2
provides three examples of small-RNA mediated
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Nucleic Acids Research,2012, Vol.40, No. 3 1247exon/intron exclusion. In all cases, we needed to screen
only a handful of RNAs before identifying active agents,
suggesting that the phenomenon is general and easily
achievable.
DISCUSSION
Control of gene expression by small RNAs within mam-
malian cells is usually associated with gene silencing in
the cytoplasm. miRNAs (31,32) and AGO protein
(16,17,26,27), however, both exist in the nucleus, suggest-
ing that recognition of nuclear RNA targets might also
help regulate cellular function. We (15,16) and others
(33,34) have observed that small RNAs can either
silence or activate gene transcription through recognition
of non-coding transcripts that overlap genes. These data
and our demonstration that duplex RNAs can affect
splicing through recognition of pre-mRNA establish the
potential for potent RNA-mediated regulation in mam-
malian cell nuclei.
Our ﬁndings are the ﬁrst example of RNA-mediated
exclusion of introns or exons from mRNA. There has
been one previous report describing RNAs that affect
exon inclusion (23), but the mechanism appears different
from the one suggested by our data. Given the rich variety
of RNA targets in the nucleus, it should not be surprising
that RNA can employ multiple mechanisms to regulate
splicing. The precedent that gene silencing by small
RNAs can be achieved by blocking transcription
through binding to non-coding transcripts or post-
transcriptionally through recognition of mRNA also
supports the hypothesis that multiple routes may also
exist for RNA-mediated control of splicing.
AGO2 is involved in RNA-mediated exon exclusion.
This may be seen as surprising because the ability of
AGO2 to induce cleavage of mRNA targets in the
cytoplasm is well known. In nuclear extracts, however,
Tuschl reported that cleavage was much weaker relative
to cytoplasmic activity and cleavage site selectivity was
greatly reduced (35). Fluorescence correlation spectros-
copy suggests that nuclear AGO complexes are much
smaller than AGO complexes in the cytoplasm (36),
providing one explanation why activities might differ.
Other reports have described post-translational modiﬁca-
tions that affect AGO2 activity (37–39), and such
modiﬁcations may play a role in targeting and activity in
the nucleus. Our results emphasize the need for experi-
menters to have an open mind regarding how AGO
might function in the nucleus and design experiments
accordingly.
We have not observed evidence of target transcript
cleavage during our studies of AGO2-mediated transcrip-
tional silencing and activation (15,16). Cleavage was not
detected by 50 RACE and expression of the targeted
non-coding transcript was unchanged during gene activa-
tion. When RIP is performed with anti-AGO2 antibody,
the target transcript is detected even though detection
involves primers that ﬂank the RNA binding site where
cleavage would be predicted to occur.
Our observation that AGO2 mediates RNA-mediated
exon exclusion without causing destruction of transcripts
in the nucleus, regardless of whether the target sequence is
within an intron or an exon, further establishes that
nuclear AGO2 function can differ signiﬁcantly from the
function of AGO2 in the cytoplasm. Understanding the
molecular basis for the different properties of AGO2 in
the nucleus and cytoplasm will be an important goal for
future studies. Nuclear AGO2 may have different
post-translational modiﬁcations or may bind to different
proteins or other cofactors. The duplex RNAs used in our
studies target sequences near splice sites and it is likely
that binding of the AGO2/RNA complex blocks the
sites and alters splicing preferences.
Synthetic RNA duplexes are widely used to modulate
gene expression and our results demonstrate that they
can also control splicing. Typically, for gene silencing,
duplexes are designed to be fully complementary and
mismatch-containing duplexes are used as controls. We
have previously shown that the introduction of mis-
matched bases relative to their mRNA targets can
permit RNA duplexes to achieve high levels of allele se-
lectivity (39). We now show that mismatched RNA
duplexes can alter splicing and help tailor the ratio of
spliced products. The use of mismatched RNA duplexes
to achieve desired selectivities emphasizes the potential to
achieve improved important properties of RNAs through
mechanism-guided duplex design.
Our data demonstrating RNA-mediated alteration of
splicing have several implications (Figure 7): (i) Small
RNAs can function together with nuclear AGO2
Figure 7. Scheme showing redirection of splicing by fully complementary and mismatch-containing duplex RNAs.
1248 Nucleic Acids Research, 2012,Vol.40, No. 3to recognize pre-mRNA transcripts and alter splicing.
This ﬁnding expands the range of RNA-mediated
control of gene expression to alternative splicing; (ii) regu-
lation of splicing is robust and reproducible, consistent
with the robustness found in endogenous regulatory
pathways. (iii) Small miRNA-like mismatch-containing
duplexes also alter splicing. miRNAs exist in the nucleus
(31,32) and our data suggest that miRNAs have the po-
tential to modulate splicing; (iv) redirecting splicing using
duplex RNAs provides an alternative to using antisense
oligonucleotides that may prove advantageous for devel-
opment of nucleic acid therapeutics and (v) mismatched
duplexes can be used if it is necessary to preserve
spliceforms that retain targeted exons, while fully comple-
mentary duplexes can be used if maximal biasing toward
exon-excluded spliceforms are required. The potential of
small RNAs to modulate alternative splicing by small
RNAs offers another layer to the subtle pattern of
RNA-mediated regulation that exists inside cells and a
new option for therapeutic development.
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